Last Updated on October 6, 2024 by The Health Master
The US Food and Drug Administration (USFDA) approved Otsuka Pharmaceutical’s brexpiprazole to treat agitation in patients with Alzheimer’s, making it the first approved drug for the indication.
The decision comes after an advisory panel in April voted that the company had enough data to identify the population in whom benefits from the treatment outweigh its risks.
Patients with Alzheimer’s sometimes show signs of extreme aggression or become restless and anxious as their brain loses its ability to negotiate with new stimulus as a result of the disease.
The approval of brexpiprazole is based on two late-stage studies, which showed significant improvement in calming agitated patients with Alzheimer’s, when compared with a placebo.
Brexpiprazole, co-developed with Lundbeck, was previously approved in the US to treat adults with major depressive disorder and schizophrenia.
USFDA gives approval for Pupil-dilating spray
USFDA gives approval for this first RSV Vaccine
USFDA gives tentative nod for ARV oral, Dolutegravir
USFDA gives approval for next generation Pneumococcal Vaccine
USFDA gives approval for this ALS drug
USFDA gives nod for Nitrofurantoin Oral Suspension USP
Surprise Inspection of 35 Medical Store: 8 Suspended, One Sealed
Govt releases Guidelines for scheme for Assistance to Medical Devices Clusters
FDA Haryana busts international racket selling spurious cancer injection, 4 arrested
USFDA gives EIR to Alembic for Jorad facility
Requirement of IP, IPRS & Impurity Standards to be part of joint inspection
NPPA to fix ceiling prices based on existing methodology
NABL accredits more Laboratories with a total number of 8,386 Laboratories
National Medical Devices Policy 2023: Salient Features
All Blood Centres / Banks to have NAT-PCR test by 2025
Moving towards zero counterfeiting to ease traceability and authentication
